A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia
Phase of Trial: Phase III
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Tedizolid (Primary) ; Linezolid
- Indications Gram-positive infections; Nosocomial pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Cubist Pharmaceuticals; Trius Therapeutics
- 14 Feb 2019 Trial has been completed in Slovakia, according to European Clinical Trials Database.
- 29 Jun 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 Status changed from recruiting to active, no longer recruiting.